Lack of COPD-Related Follow-Up Visits and Pharmacological Treatment in Swedish Primary and Secondary Care

References

• Global Initiative for Chronic Obstructive Lung Disease. 2020 Report: global strategy for the diagnosis, management and prevention of COPD; 2020. Available from: https://goldcopd.org. Accessed November 2021.
   Google Scholar
• Calverley P, Bellamy D. The challenge of providing better care for patients with chronic obstructive pulmonary disease: the poor relation of airways obstruction? Thorax. 2000;55(1):78–82. doi:10.1136/thorax.55.1.78
   PubMed Web of Science ®Google Scholar
• Chetty U, McLean G, Morrison D, et al. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e321–e328. doi:10.3399/bjgp17X690605
   PubMed Web of Science ®Google Scholar
• Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–1257. doi:10.1183/09031936.00133805
   PubMed Web of Science ®Google Scholar
• Andell P, Koul S, Martinsson A, et al. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart. 2014;1(1):e000002. doi:10.1136/openhrt-2013-000002
   PubMedGoogle Scholar
• Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC
   PubMed Web of Science ®Google Scholar
• National Board of Health and Welfare. Nationella riktlinjer för astma och KOL; 2020. Available from: www.socialstyrelsen.se. Accessed January 2022.
   Google Scholar
• Ramakrishnan S, Janssens W, Burgel P-R, et al. Standardisation of clinical assessment, management and follow-up of acute hospitalised exacerbation of COPD: a Europe-Wide Consensus. Int J Chron Obstruct Pulmon Dis. 2021;16:321–332. doi:10.2147/COPD.S287705
   PubMed Web of Science ®Google Scholar
• Park HJ, Byun MK, Kim T, et al. Frequent outpatient visits prevent exacerbation of chronic obstructive pulmonary disease. Sci Rep. 2020;10(1):6049. doi:10.1038/s41598-020-63064-x
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq433
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144
   Web of Science ®Google Scholar
• Larsson K, Janson C, Lisspers K, et al. The impact of exacerbation frequency on clinical and economic outcomes in Swedish COPD patients: the arctic study. Int J Chron Obstruct Pulmon Dis. 2021;16:701–713. doi:10.2147/COPD.S297943
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Smeeth L, et al. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC
   PubMed Web of Science ®Google Scholar
• Janson C, Nwaru BI, Wiklund F, et al. Management and risk of mortality in patients hospitalised due to a first severe COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2020;15:2673–2682. doi:10.2147/COPD.S276819
   PubMed Web of Science ®Google Scholar
• Fawcett J. The metaparadigm of nursing: present status and future refinements. Image J Nurs Sch. 1984;16(3):84–89. doi:10.1111/j.1547-5069.1984.tb01393.x
   PubMedGoogle Scholar
• Rosa F, Bagnasco A, Ghirotto L, et al. Experiences of older people following an acute exacerbation of chronic obstructive pulmonary disease: a phenomenological study. J Clin Nurs. 2018;27(5–6):e1110–e1119. doi:10.1111/jocn.14189
   PubMed Web of Science ®Google Scholar
• Camac ER, Voelker H, Criner GJ. Impact of COPD exacerbations leading to hospitalization on general and disease-specific quality of life. Respir Med. 2021;186:106526. doi:10.1016/j.rmed.2021.106526
   PubMed Web of Science ®Google Scholar
• Long J, Ouyang Y, Duan H, et al. Multiple factor analysis of depression and/or anxiety in patients with acute exacerbation chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1449–1464. doi:10.2147/COPD.S245842
   PubMed Web of Science ®Google Scholar
• Lisspers K, Johansson G, Jansson C, et al. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. Respir Med. 2014;108(9):1345–1354. doi:10.1016/j.rmed.2014.06.002
   PubMed Web of Science ®Google Scholar
• Swanson JO, Vogt V, Sundmacher L, et al. Continuity of care and its effect on readmissions for COPD patients: a comparative study of Norway and Germany. Health Policy. 2018;122(7):737–745. doi:10.1016/j.healthpol.2018.05.013
   PubMed Web of Science ®Google Scholar
• Lin IP, Wu SC, Huang ST. continuity of care and avoidable hospitalizations for chronic obstructive pulmonary disease (COPD). J Am Board Fam Med. 2015;28(2):222–230. doi:10.3122/jabfm.2015.02.140141
   PubMed Web of Science ®Google Scholar
• Hsieh PL, Yang FC, Hu YF, et al. Continuity of care and the quality of life among patients with Type 2 diabetes mellitus: a cross-sectional study in Taiwan. Healthcare. 2020;8:486.
   Web of Science ®Google Scholar
• Spyratos D, Chloros D, Michalopoulou D, et al. Underdiagnosis, false diagnosis and treatment of COPD in a selected population in Northern Greece. Eur J Gen Pract. 2021;27(1):97–102. doi:10.1080/13814788.2021.1912729
   PubMed Web of Science ®Google Scholar
• Sandelowsky H, Hylander I, Krakau I, et al. Time pressured deprioritization of COPD in primary care: a qualitative study. Scand J Prim Health Care. 2016;34(1):55–65. doi:10.3109/02813432.2015.1132892
   PubMed Web of Science ®Google Scholar
• Sundh J, Åberg J, Hasselgren M, et al. Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014. Eur Clin Respir J. 2017;4(1):1409060. doi:10.1080/20018525.2017.1409060
   PubMed Web of Science ®Google Scholar
• Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16(5):802–807. doi:10.1183/09031936.00.16580200
   PubMed Web of Science ®Google Scholar
• Janson C, Accordini S, Cazzoletti L, et al. Pharmacological treatment of asthma in a cohort of adults during a 20-year period: results from the European Community Respiratory Health Survey I, II and III. ERJ Open Res. 2019;5(1):00073–2018. doi:10.1183/23120541.00073-2018
   PubMedGoogle Scholar
• Ekström M, Nwaru BI, Wiklund F, et al. Risk of rehospitalization and death in patients hospitalized due to asthma. J Allergy Clin Immunol Pract. 2021;9(5):1960–1968.e4. doi:10.1016/j.jaip.2020.12.030
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators; Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Tkacz J, Evans KA, Touchette DR, et al. PRIMUS - Prompt initiation of maintenance therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:329–342. doi:10.2147/COPD.S347735
   PubMed Web of Science ®Google Scholar
• Bogart M, Glassberg MB, Reinsch T, et al. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting. Respir Med. 2018;145:138–144. doi:10.1016/j.rmed.2018.10.013
   PubMed Web of Science ®Google Scholar
• Coutinho AD, Lokhandwala T, Boggs R, et al. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population. Int J Chron Obstruct Pulmon Dis. 2016;11:1223–1231. doi:10.2147/COPD.S102570
   PubMed Web of Science ®Google Scholar
• Stallberg B, Janson C, Johansson G, et al. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J. 2014;23(1):38–45. doi:10.4104/pcrj.2013.00106
   PubMedGoogle Scholar
• Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med. 2011;5(5):647–662. doi:10.1586/ers.11.62
   PubMed Web of Science ®Google Scholar
• Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888. doi:10.2147/COPD.S49621
   PubMed Web of Science ®Google Scholar